Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
HTR7 3363 LOXAPINE CHEMBL831 binder DrugBank
HTR7 3363 DEXAMETHASONE CHEMBL384467 NCI 9166758
HTR7 3363 LY2590443 CHEMBL3545220 antagonist ChemblInteractions
HTR7 3363 BIFEPRUNOX CHEMBL218166 TdgClinicalTrial
HTR7 3363 ASENAPINE (CHEMBL3187365) CHEMBL3187365 TdgClinicalTrial
HTR7 3363 PARDOPRUNOX CHEMBL2103832 TdgClinicalTrial
HTR7 3363 LURASIDONE CHEMBL1237021 antagonist TdgClinicalTrial, DrugBank 23545936
HTR7 3363 ZIPRASIDONE CHEMBL708 TEND
HTR7 3363 ARIPIPRAZOLE CHEMBL1112 antagonist DrugBank 17848919
HTR7 3363 ELETRIPTAN CHEMBL1510 agonist DrugBank 17139284, 17016423
HTR7 3363 OLANZAPINE CHEMBL715 antagonist TdgClinicalTrial, DrugBank 17848919
HTR7 3363 CLOZAPINE CHEMBL42 antagonist NCI, DrugBank 17848919, 7908055
HTR7 3363 AMISULPRIDE CHEMBL243712 antagonist DrugBank 19337725
HTR7 3363 VORTIOXETINE CHEMBL2104993 antagonist TdgClinicalTrial, DrugBank 21486038
HTR7 3363 BREXPIPRAZOLE CHEMBL2105760 TdgClinicalTrial
HTR7 3363 MIRTAZAPINE CHEMBL654 binding DrugBank 15771415, 3419539
HTR7 3363 AMOXAPINE CHEMBL1113 antagonist DrugBank 7908055
HTR7 3363 CHLORPROMAZINE CHEMBL71 NCI 7908055
HTR7 3363 ILOPERIDONE CHEMBL14376 antagonist TdgClinicalTrial, DrugBank 23272794
HTR7 3363 METHYSERGIDE CHEMBL1065 antagonist TdgClinicalTrial, TEND, DrugBank 14501155
HTR7 3363 CABERGOLINE CHEMBL1201087 antagonist DrugBank 18992242
HTR7 3363 MIANSERIN CHEMBL6437 antagonist DrugBank 10997731

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
HTR7 rs7905446 TT fluoxetine efficacy yes A 'good' response was determined as a 50% reduction in symptoms or episode frequency during the course of the illness. This analysis was carried out on patients who were treated with fluoxetine or paroxetine. This association remained statistically significant in the paroxetine group, but significance was lost in the fluoxetine group. Genotype TT is associated with decreased response to fluoxetine or paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT. 30874608 1450372683
HTR7 rs7905446 TT escitalopram efficacy no Although there was no significant association of this variant with treatment response in the combined group of patients treated with escitalopram or nortriptyline, there was a significant association in the group of escitalopram-treated patients. Genotype TT is not associated with response to escitalopram or nortriptyline in people with Depression as compared to genotypes GG + GT. 30874608 1450372728
HTR7 rs7905446 TT atomoxetine efficacy yes The TT genotype was associated with non-remission, white the GG and GT genotypes were associated with treatment remission at 6 weeks. This association was seen with SSRI and SNRI treatment however, the exact drugs used in treatment were not specified. Genotype TT is associated with decreased response to atomoxetine, desvenlafaxine, duloxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Depression as compared to genotypes GG + GT. 30874608 1450372702
HTR7 rs7905446 TT Selective serotonin reuptake inhibitors efficacy yes The TT genotype was associated with non-remission, white the GG and GT genotypes were associated with treatment remission at 6 weeks. Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors in people with Depression as compared to genotypes GG + GT. 30874608 1450372709
HTR7 rs7905446 TT escitalopram efficacy yes The GG and GT genotypes were associated with treatment remission. Genotype TT is associated with decreased response to escitalopram in people with Depression as compared to genotypes GG + GT. 30874608 1450372715
HTR7 rs7905446 TT paroxetine efficacy yes A 'good' response was determined as a 50% reduction in symptoms or episode frequency during the course of the illness. Genotype TT is associated with decreased response to paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT. 30874608 1450372675
HTR7 rs7905446 TT antidepressants efficacy yes The TT genotype was associated with non-remission, white the GG and GT genotypes were associated with treatment remission at 6 weeks. Genotype TT is associated with decreased response to antidepressants in people with Depression as compared to genotypes GG + GT. 30874608 1450372692
HTR7 rs7905446 TT nortriptyline efficacy no Genotype TT is not associated with response to nortriptyline in people with Depression as compared to genotypes GG + GT. 30874608 1450372722